ASIT biotech is a clinical stage (Phase 3) biopharmaceutical company publicly listed on EURONEXT (Brussels & Paris).
ASIT biotech’s mission is to lead an evolution in allergy therapeutics by creating a new generation of highly effective and efficient immunotherapy options for respiratory and food allergies. Our goal is to generate breakthrough treatments that deliver rapid, recognizable improvement in the life of allergy patients, within weeks rather than months or years following treatment initiation.
- The Walloon Region appeals against the judgment approving the judicial reorganisation plan of ASIT biotech Thursday, 25 February 2021
- The commercial court of Liège has approved the restructuring plan of ASIT biotech Tuesday, 09 February 2021
- The reorganisation plan of ASIT biotech has been approved by the majority of creditors Wednesday, 03 February 2021 All ASIT news